S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
NASDAQ:SNDX

Syndax Pharmaceuticals SEC Filings & 10K Form

$15.23
-0.74 (-4.63%)
(As of 12/1/2021 12:00 AM ET)
Add
Compare
Today's Range
$15.09
$17.16
50-Day Range
$15.23
$20.24
52-Week Range
$13.02
$27.85
Volume
474,776 shs
Average Volume
633,067 shs
Market Capitalization
$752.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.41

Syndax Pharmaceuticals (NASDAQ:SNDX) SEC Filings

DateFilerForm TypeView
09/17/2021
3:32 PM
Huber Martin H. Jr. (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/15/2021
3:16 PM
Metzger Michael A (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/20/2021
3:46 PM
Egros Fabrice (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/03/2021
2:15 PM
Access Industries Holdings LLC (Filed by)
Syndax Pharmaceuticals (Subject)
Form SC 13D
04/22/2021
4:06 PM
Podlesak Dennis (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
04/01/2021
4:08 PM
Syndax Pharmaceuticals (Filer)
Form DEF 14A
03/24/2021
3:56 PM
Syndax Pharmaceuticals (Filer)
Form S-3ASR
03/24/2021
3:53 PM
Syndax Pharmaceuticals (Filer)
Form RW
03/03/2021
3:16 PM
Egros Fabrice (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/16/2021
10:32 AM
Avidity Partners Management LP (Filed by)
Syndax Pharmaceuticals (Subject)
Form SC 13G/A
02/12/2021
4:16 PM
BIOTECHNOLOGY VALUE FUND L P (Filed by)
Syndax Pharmaceuticals (Subject)
Form SC 13G/A
02/10/2021
3:23 PM
Morrison Briggs (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/05/2021
3:30 PM
Syndax Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/05/2021
3:18 PM
Meury William (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/05/2021
3:18 PM
Legault Pierre (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/05/2021
3:18 PM
Egros Fabrice (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/05/2021
3:18 PM
Katkin Keith (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/05/2021
3:18 PM
Jarrett Jennifer (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/04/2021
9:27 AM
Syndax Pharmaceuticals (Subject)
WELLINGTON MANAGEMENT GROUP LLP (Filed by)
Form SC 13G/A
02/03/2021
4:53 PM
Metzger Michael A (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/10/2020
7:12 AM
Syndax Pharmaceuticals (Subject)
WELLINGTON MANAGEMENT GROUP LLP (Filed by)
Form SC 13G/A
12/09/2020
3:05 PM
Syndax Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/09/2020
3:02 PM
Syndax Pharmaceuticals (Filer)
Form 424B5
12/07/2020
4:23 PM
Syndax Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/07/2020
4:22 PM
Syndax Pharmaceuticals (Filer)
Form 424B5
12/03/2020
5:05 PM
Metzger Michael A (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/25/2020
3:38 PM
Ordentlich Peter (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/12/2020
4:55 PM
Morrison Briggs (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/06/2020
4:55 PM
Metzger Michael A (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/04/2020
4:05 PM
Avidity Partners Management LP (Filed by)
Syndax Pharmaceuticals (Subject)
Form SC 13G
11/02/2020
3:07 PM
Syndax Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/09/2020
2:52 PM
BlackRock Inc. (Filed by)
Syndax Pharmaceuticals (Subject)
Form SC 13G/A
08/06/2020
3:18 PM
Syndax Pharmaceuticals (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
08/06/2020
3:05 PM
Syndax Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/13/2020
7:28 AM
Karydas Daphne (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
07/08/2020
3:11 PM
Meyers Michael L. (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/07/2020
6:16 AM
Syndax Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/11/2020
4:16 PM
Boxer Capital, LLC (Filed by)
Syndax Pharmaceuticals (Subject)
Form SC 13G
05/04/2020
7:49 AM
Syndax Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/30/2020
5:45 AM
Syndax Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/30/2020
5:21 AM
Syndax Pharmaceuticals (Filer)
Form 424B5
03/05/2020
4:29 PM
Syndax Pharmaceuticals (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/06/2020
8:10 AM
BlackRock Inc. (Filed by)
Syndax Pharmaceuticals (Subject)
Form SC 13G/A
02/04/2020
8:12 AM
Syndax Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/28/2020
10:49 AM
Syndax Pharmaceuticals (Subject)
WELLINGTON MANAGEMENT GROUP LLP (Filed by)
Form SC 13G/A
12/10/2019
6:00 AM
Syndax Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/07/2019
3:06 PM
Syndax Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/07/2019
3:02 PM
Syndax Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/11/2019
5:33 AM
Morrison Briggs (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/09/2019
4:27 PM
Access Industries Holdings LLC (Filed by)
Syndax Pharmaceuticals (Subject)
Form SC 13G
10/07/2019
6:01 AM
Syndax Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/10/2019
11:15 PM
Syndax Pharmaceuticals (Filer)
Form EFFECT
09/10/2019
3:30 PM
Syndax Pharmaceuticals (Filer)
Form 424B5
08/30/2019
3:08 PM
Syndax Pharmaceuticals (Filer)
Form S-3
Registration statement under Securities Act of 1933  
08/07/2019
3:17 PM
Syndax Pharmaceuticals (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
08/07/2019
3:11 PM
Syndax Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/07/2019
3:05 PM
Syndax Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/08/2019
3:02 PM
Syndax Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/08/2019
3:01 PM
Metzger Michael A (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/12/2019
8:00 AM
Podlesak Dennis (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/12/2019
8:00 AM
Meury William (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/12/2019
8:00 AM
Legault Pierre (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/12/2019
8:00 AM
Katkin Keith (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/12/2019
8:00 AM
Jarrett Jennifer (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/12/2019
8:00 AM
Egros Fabrice (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/11/2019
3:05 PM
Syndax Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/13/2019
3:11 PM
Morrison Briggs (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/08/2019
4:08 PM
Syndax Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/06/2019
3:10 PM
Syndax Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/30/2019
3:02 PM
Syndax Pharmaceuticals (Filer)
Form DEF 14A
04/08/2019
1:48 PM
ADAGE CAPITAL PARTNERS GP, L.L.C. (Filed by)
Syndax Pharmaceuticals (Subject)
Form SC 13G
03/29/2019
3:13 PM
Syndax Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/28/2019
1:01 PM
Syndax Pharmaceuticals (Filer)
Form CT ORDER
03/27/2019
8:51 PM
Syndax Pharmaceuticals (Filer)
Form 424B5
03/25/2019
3:03 PM
Meyers Michael L. (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4/A
03/22/2019
3:05 PM
Meyers Michael L. (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/18/2019
3:52 PM
Syndax Pharmaceuticals (Filer)
Form 10-K/A
03/07/2019
3:10 PM
Syndax Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/14/2019
3:22 PM
BIOTECHNOLOGY VALUE FUND L P (Filed by)
Syndax Pharmaceuticals (Subject)
Form SC 13G/A
02/14/2019
10:41 AM
683 Capital Management, LLC (Filed by)
Syndax Pharmaceuticals (Subject)
Form SC 13G/A
02/12/2019
3:02 PM
Syndax Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/12/2019
8:50 AM
Syndax Pharmaceuticals (Subject)
Form SC 13G/A
02/08/2019
3:28 PM
Ordentlich Peter (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/08/2019
3:27 PM
Shea Richard P (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/08/2019
3:27 PM
Meyers Michael L. (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/08/2019
3:27 PM
Metzger Michael A (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/29/2018
3:03 PM
683 Capital Management, LLC (Filed by)
Syndax Pharmaceuticals (Subject)
Form SC 13G
11/07/2018
3:02 PM
Meyers Michael L. (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/05/2018
4:01 PM
Syndax Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/05/2018
3:02 PM
Syndax Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/27/2018
4:42 PM
Jarrett Jennifer (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/27/2018
4:42 PM
Meury William (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/27/2018
4:38 PM
Jarrett Jennifer (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
09/27/2018
4:38 PM
Meury William (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
09/26/2018
3:02 PM
Syndax Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/29/2018
2:01 PM
Syndax Pharmaceuticals (Filer)
Form CT ORDER
08/08/2018
3:16 PM
Syndax Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/07/2018
3:02 PM
Syndax Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/20/2018
6:48 PM
BIOTECHNOLOGY VALUE FUND II LP (Reporting)
BIOTECHNOLOGY VALUE FUND L P (Reporting)
Biotechnology Value Trading Fund OS LP (Reporting)
BVF INC/IL (Reporting)
BVF PARTNERS L P/IL (Reporting)
BVF Partners OS Ltd. (Reporting)
LAMPERT MARK N (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/20/2018
3:34 PM
Syndax Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
This page was last updated on 12/2/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.